Efficacy and safety of deferasirox in thalassemia major patients after repeated blood transfusion: A single-center study

Jinal M Modh; Amita R Kubavat; Anil P Singh

doi:10.5455/njppp.2024.13.072742024202082024

2024, Vol: 14, Issue: 12

14 / 12Current Issue Online First Archive Aims and Scope Abstracting & Indexing Most Accessed Articles Most Downloaded Articles Most Cited Articles

Required files to be uploaded

NJPPP Manuscript Submission Form

« Previous Article

Original Research
Online Published: 12 Aug 2024

Natl J Physiol Pharm Pharmacol. 2024; 14(10): 2266-2271

doi: 10.5455/njppp.2024.13.072742024202082024

Efficacy and safety of deferasirox in thalassemia major patients after repeated blood transfusion: A single-center study

Jinal M Modh, Amita R Kubavat, Anil P Singh.

Abstract
Background: Patients with β-thalassemia major (TM) require lifelong blood transfusions, leading to iron overload, where active intervention is required.

Aims and Objectives: The aim of the study was to evaluate real-world efficacy and safety of deferasirox (DFX) in TM patients at a tertiary care teaching hospital.

Materials and Methods: A prospective observational study was conducted at thalassemia ward in a tertiary care teaching hospital in Gujarat for a period of 15 months from April 2021 to July 2022. A total of 100 patients were analyzed during the study period. Patient’s demographic profile, laboratory investigation, and treatment details were analyzed using descriptive statistics. Statistical analysis was done through the statistical software GraphPad Prism 9.4.1 (681).

Results: A total of 100 patients were included in the study. A serial significant decrease in median serum ferritin levels was observed in >13 years age group after initiation of DFX. A significant increase in the median dose of DFX was observed at 12 months in the age group of 2–≤13 years as compared to baseline (P < 0.05). Adverse reactions observed during the study were increased bilirubin level, increased alanine aminotransferase, and increased serum creatinine, rashes with itching, and arthralgia.

Conclusion: A greater reduction in median serum ferritin levels was observed in the adult age group compared to pediatric patients.

Key words: Thalassemia Major; Deferasirox; Iron Chelation; Safety; Serum Ferritin

	ARTICLE TOOLS
	Abstract
	PDF Fulltext
	How to cite this article
	Citation Tools
	Related Records
	Articles by Jinal M Modh Articles by Amita R Kubavat Articles by Anil P Singh
	on Google
	on Google Scholar

How to Cite this Article

Pubmed Style

Modh JM, Kubavat AR, Singh AP. Efficacy and safety of deferasirox in thalassemia major patients after repeated blood transfusion: A single-center study. Natl J Physiol Pharm Pharmacol. 2024; 14(10): 2266-2271. doi:10.5455/njppp.2024.13.072742024202082024

Web Style

Modh JM, Kubavat AR, Singh AP. Efficacy and safety of deferasirox in thalassemia major patients after repeated blood transfusion: A single-center study. https://www.njppp.com/?mno=208262 [Access: January 18, 2025]. doi:10.5455/njppp.2024.13.072742024202082024

AMA (American Medical Association) Style

Modh JM, Kubavat AR, Singh AP. Efficacy and safety of deferasirox in thalassemia major patients after repeated blood transfusion: A single-center study. Natl J Physiol Pharm Pharmacol. 2024; 14(10): 2266-2271. doi:10.5455/njppp.2024.13.072742024202082024

Vancouver/ICMJE Style

Modh JM, Kubavat AR, Singh AP. Efficacy and safety of deferasirox in thalassemia major patients after repeated blood transfusion: A single-center study. Natl J Physiol Pharm Pharmacol. (2024), [cited January 18, 2025]; 14(10): 2266-2271. doi:10.5455/njppp.2024.13.072742024202082024

Harvard Style

Modh, J. M., Kubavat, . A. R. & Singh, . A. P. (2024) Efficacy and safety of deferasirox in thalassemia major patients after repeated blood transfusion: A single-center study. Natl J Physiol Pharm Pharmacol, 14 (10), 2266-2271. doi:10.5455/njppp.2024.13.072742024202082024

Turabian Style

Modh, Jinal M, Amita R Kubavat, and Anil P Singh. 2024. Efficacy and safety of deferasirox in thalassemia major patients after repeated blood transfusion: A single-center study. National Journal of Physiology, Pharmacy and Pharmacology, 14 (10), 2266-2271. doi:10.5455/njppp.2024.13.072742024202082024

Chicago Style

Modh, Jinal M, Amita R Kubavat, and Anil P Singh. "Efficacy and safety of deferasirox in thalassemia major patients after repeated blood transfusion: A single-center study." National Journal of Physiology, Pharmacy and Pharmacology 14 (2024), 2266-2271. doi:10.5455/njppp.2024.13.072742024202082024

MLA (The Modern Language Association) Style

Modh, Jinal M, Amita R Kubavat, and Anil P Singh. "Efficacy and safety of deferasirox in thalassemia major patients after repeated blood transfusion: A single-center study." National Journal of Physiology, Pharmacy and Pharmacology 14.10 (2024), 2266-2271. Print. doi:10.5455/njppp.2024.13.072742024202082024

APA (American Psychological Association) Style

Modh, J. M., Kubavat, . A. R. & Singh, . A. P. (2024) Efficacy and safety of deferasirox in thalassemia major patients after repeated blood transfusion: A single-center study. National Journal of Physiology, Pharmacy and Pharmacology, 14 (10), 2266-2271. doi:10.5455/njppp.2024.13.072742024202082024

Author Login Reviewer Login About Publisher Editorial Policies Editorial Review Policy Peer Review Policy Editorial & Peer Review Process Publication Ethics and Publication Malpractice Statement Conflict of Interest Policy Plagiarism Policy Protection of Research Participants (Statement On Human And Animal Rights)Corrections, Retractions & Expressions of Concern Self-Archiving Policies Digital Archiving & Preservation Policies Statement of Informed Consent Advertising Policy Terms of Use License Information Copyright Information

About National Journal of Physiology, Pharmacy and Pharmacology

Contact Information

How to cite this article